Form 8K CalciMedica Inc For: 10 November
- Investing.com
Metrics to compare | CALC | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCALCPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.6x | −1.0x | −0.2x | |
PEG Ratio | −0.01 | −0.02 | 0.00 | |
Price / Book | 2.0x | 1.7x | 2.6x | |
Price / LTM Sales | - | 7.8x | 2.7x | |
Upside (Analyst Target) | - | 231.0% | 68.5% | |
Fair Value Upside | Unlock | 1.4% | 11.5% | Unlock |
CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. The company also develops Auxora for the treatment of ulcerative colitis, traumatic brain injury, and allergic asthma; and oral CRAC channel inhibitors for use in chronic inflammatory and immunologic disease. The company is based in La Jolla, California.